Solid lipid nanoparticles as drug carriers. I. Incorporation and retention of the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate

Polymeric Nanoparticles for Enhancing Antiretroviral Drug Therapy

“…• C over a prolonged period of time was reported in their previous study (Heiati et al 1997), in this study the incubation of SLNs in plasma resulted in rapid release of AZT. The authors indicated that it could be due to enzymatic degradation of the phospholipid membranes, an interaction with specific plasma proteins, or an interaction with lipoproteins.…”

“…Hence, this study concluded that loading and retention of AZT-P was dependent on the phospholipid coating on the SLN surface and was independent of the trilaurin solid core (Heiati et al 1997). A follow-up study with AZT-P nanoparticles involved coating of the SLNs with PEG and investigating its biodistribution (Heiati, Tawashi, and Phillips 1998).…”

“…SLNs comprising AZT-palmitate and trilaurin (TL) as the solid core with dipalmitoylphosphatidylcholine (DPPC) and mixture of DPPC and dimyristoylphosphatidylglycerol (DMPG) were previously prepared by Heiati et al (1997) and Heiati, Tawashi, and Phillips (1998). While the incorporation of the hydrophilic AZT was minimal, the incorporation of its ester form, AZT-Palmitate (AZT-P), increased with increasing concentration of phospholipids content and was independent of the amount of trilaurin used.…”

Solid lipid nanoparticles for ocular drug delivery

“…The longer chain triglycerides have higher melting points, are believed to be more stable, and expected to produce better SLNs (Radomska-Soukharev, 2007). Many triglycerides such as tricarpin (Domb, 1995), trilaurin (Domb, 1995;Westesen & Bunjes, 1995;Bunjes et al, 1996;Heiati et al, 1997;Schwarz & Mehnert, 1997;zur Mühlen et al, 1998), trimyristin (Westesen & Bunjes, 1995;Bunjes et al, 1996;, tripalmitin (Westesen & Bunjes, 1995;Bunjes et al, 1996;Westesen & Siekmann, 1997), tristearin (Domb, 1995;Westesen & Bunjes, 1995;Bunjes et al, 1996), and hydrated coco-glucerides (Almeida et al, 1997) have been used in the preparation of SLNs (Mehnert & Mäder, 2001). These widely used triglycerides are considered as suitable solid lipid core materials for the production of particles because their melting point is well above body temperature to allow controlled drug release, but sufficiently low to assure solidification after melt homogenization (Bunjes et al, 1996).…”

Effect of Modification Protocols on the Effectiveness of Gold Nanoparticles as Drug Delivery Vehicles for Killing of Breast Cancer Cells

“…For example, the ability of insoluble drugs combined with nanoparticles to increase drug uptake by malignant cells and control drug release in specific sites is significantly improved when compared with free drugs. [9] Various nanoparticles have been used in TDDSs such as solid lipid nanoparticles, [10] liposomes, [11] superparamagnetic nanoparticles, [12] and quantum dots. [13] Gold nanoparticles (AuNPs) are well suited to a range of medical applications due to their easy preparation and bioconjugation ability to bind to thiol groups and improved surface catalytic activity.…”